US Stock MarketDetailed Quotes

BLCO Bausch + Lomb Corp.

Watchlist
  • 18.000
  • +0.050+0.28%
Close Dec 20 16:00 ET
  • 18.600
  • +0.600+3.33%
Post 20:01 ET
6.34BMarket Cap-17.31P/E (TTM)

About Bausch + Lomb Corp. Company

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Company Profile

SymbolBLCO
Company NameBausch + Lomb Corp.
Listing DateMay 6, 2022
Issue Price18.00
Founded1853
CEOMr. Brenton L. Saunders
MarketNYSE
Employees13300
Fiscal Year Ends12-31
Address520 Applewood Crescent
CityVaughan
ProvinceOntario
CountryCanada
Zip CodeL4K 4B4
Phone1-905-695-7700

Company Executives

  • Name
  • Position
  • Salary
  • Brenton L. Saunders
  • Chief Executive Officer and Chairman of the Board
  • 45.31M
  • Sam A. Eldessouky
  • Chief Financial Officer and Executive Vice President
  • 4.76M
  • Dr. Yehia Hashad, M.D.
  • Executive Vice President, Research and Development and Chief Medical Officer
  • 2.66M
  • Frederick J. Munsch
  • Senior Vice President, Controller and Chief Accounting Officer
  • --
  • A. Robert D. Bailey
  • Executive Vice President and Chief Legal Officer
  • --
  • Andrew J. Stewart
  • President, Global Pharmaceuticals and International Consumer
  • 1.93M
  • Luc Bonnefoy
  • President, Surgical
  • --
  • Karen L. Ling
  • Independent Director
  • --
  • Sarah B. Kavanagh
  • Independent Director
  • 337.50K
  • Nathalie Bernier, F.C.A.
  • Independent Director
  • 324.95K
  • Thomas W. Ross, Sr
  • Lead Independent Director
  • 396.30K
  • John A. Paulson
  • Independent Director
  • 312.46K
  • Brett M. Icahn
  • Independent Director
  • 312.50K
  • Dr. Andrew C. von Eschenbach, M.D.
  • Independent Director
  • 327.50K
  • Russel C. Robertson
  • Independent Director
  • 327.45K
  • Gary Hu
  • Independent Director
  • 335.00K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.